Product logins

Find logins to all Clarivate products below.


Gynecological Devices | Market Insights | Europe (Supplemental) | 2024

The European gynecological device market was negatively impacted by the COVID-19 pandemic. However, the overall market for gynecological devices will grow marginally over the forecast period. This growth will primarily be driven by increasing awareness and education about gynecological health, as well as the continued adoption of technologies that enable treatments in non-hospital settings.

This Medtech 360 Report provides high-level market metrics for gynecological devices in Europe, including country-level data for major countries and aggregate data for the rest of Europe from 2019 through 2032.

Related Medtech Insights Reports

Report
Interventional Cardiology Devices – Market Insights – Europe
The European interventional cardiology device market is highly competitive and poised for moderate growth over the forecast period, driven by increasing PCI volumes for complex CAD cases and the…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Europe
The European EP mapping and ablation device market will grow moderately through 2035, driven by the rising prevalence of cardiac arrhythmias, improved access to treatment, advancements in ablation…
Report
Aortic Repair Devices – Market Insights – Europe
The European aortic stent graft market is the primary driver of growth in the aortic repair device market and will drive revenue expansion over the forecast period, supported by ongoing innovation…
Report
Cardiac Rhythm Management Devices – Market Insights – Europe
The European CRM device market will continue to grow modestly over the forecast period because of rising ICM procedure volumes, the introduction of dual-chamber leadless pacemakers, and increased…
Report
Gastrointestinal Endoscopy Devices – Market Insights – Europe
The European GI endoscopy device market will be driven primarily by the high incidence of gastric cancer and CRC in the region. Market growth will be supported by nationwide CRC and GI cancer…